India, July 7 -- Alamar Biosciences, Inc. (ALMR), a commercial-stage proteomics company, announced on Tuesday the commercial launch of a multiplexed blood-based immunoassay for eMTBR-Tau, a biomarker associated with Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline and pathological changes in the brain, including the accumulation of amyloid plaques and tau tangles. The biomarker eMTBR-Tau is blood-based and associated with neurofibrillary tau tangles, a pathological feature of Alzheimer's disease. The biomarker may support disease staging, patient stratification, and monitoring of biological responses to tau-targeted therapies. The eMTBR-Tau assay was designed to measure ...